Estimated disease-free survival 97.5 ± 1.3 and 90.2 ± 2.3 percent with chemotherapy plus blinatumomab, chemo alone in average-risk patients
THURSDAY, Dec. 12, 2024 (HealthDay News) — For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high risk for relapse, adding blinatumomab to combination chemotherapy is associated with improved disease-free survival, according to a study published online Dec. 7 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held from Dec. 7 to 10 in San Diego.
Sumit Gupta, Ph.D., from the University of Toronto, and colleagues conducted a phase 3 trial involving children with newly diagnosed standard-risk B-cell ALL who had an average or high risk for relapse. A total of 1,440 patients were randomly assigned to receive chemotherapy alone or chemotherapy plus blinatumomab; the results from the first interim efficacy analysis, which included 722 and 718 patients, respectively, were reviewed.
The researchers found that the estimated three-year disease-free survival was 96.0 ± 1.2 percent with blinatumomab and chemotherapy and 87.9 ± 2.1 percent with chemotherapy alone at a median follow-up of 2.5 years (difference in restricted mean survival time, 72 days). Among patients with an average relapse risk, the estimated three-year disease-free survival was 97.5 ± 1.3 percent with blinatumomab and chemotherapy and 90.2 ± 2.3 percent with chemotherapy alone; the corresponding values were 94.1 ± 2.5 percent and 84.8 ± 3.8 percent, respectively, among those with a high relapse risk.
“The addition of blinatumomab to standard chemotherapy resulted in a significant improvement in disease-free survival,” the authors write. “This improvement was consistent across subgroups defined according to patient-related or disease-related characteristics.”
Several authors disclosed ties to pharmaceutical companies, including Amgen, which manufactures blinatumomab and contributed funding for the study.
Abstract/Full Text (subscription or payment may be required)
Exercise Intervention Linked to Improved Attention, Memory in Breast Cancer .jpg)
Cancer Survivors Have Lower Levels of Physical Activity 
Childhood Cancer Survivors Often Have Mental Distress in Adulthood 
Blinatumomab Improves Event-Free Survival in Children With High-Risk B-Cell ALL .jpg)
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers 
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy 
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions 
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis 
